FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to medicine and pharmaceutics, namely discloses the use of a CXCL8 inhibitor or a pharmaceutical composition containing a CXCL8 inhibitor and at least one inert pharmaceutically acceptable excipient, in treating a patient with pneumonia caused by COVID-19, wherein said CXCL8 inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof. In general formula (I), where R1 is selected from linear or branched C1-C6 alkyl, benzoyl, phenoxy and trifluoromethanesulfonyloxy; R2 is selected from a hydrogen atom and a linear or branched C1-C3 alkyl; and R3 is a linear or branched C1-C6 alkyl or trifluoromethyl. EFFECT: use of the invention enables the effective treatment of a patient with pneumonia caused by COVID-19.
11 cl, 1 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-8 INHIBITORS FOR USE IN TREATMENT AND/OR PREVENTION OF SECONDARY BACTERIAL INFECTIONS | 2018 |
|
RU2781280C2 |
| IL-8 INHIBITORS FOR USE IN TREATMENT OF SOME SARCOMAS | 2018 |
|
RU2787821C2 |
| (2R)-2-[(4-SULPHONYL)AMINOPHENYL]PROPANAMIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2007 |
|
RU2457201C2 |
| AMIDINES AND THEIR DERIVATIVE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2004 |
|
RU2375346C2 |
| 2-ARYLACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2004 |
|
RU2356887C2 |
| HYDROBROMIDE SALT OF N-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL)-N'-(3-FLUORO-2-METHYLPHENYL)UREA | 2014 |
|
RU2685408C1 |
| SULFONIC ACIDS, DERIVATIVES OF SAID ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2004 |
|
RU2345063C2 |
| RESPIRATORY INTRODUCTION OF TISSUE FACTOR PATHWAY INHIBITOR IN INFLAMMATORY CONDITIONS INVOLVING RESPIRATORY TRACT | 2006 |
|
RU2496516C2 |
| CXCL8-BINDING NUCLEIC ACIDS | 2019 |
|
RU2815444C2 |
| 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2005 |
|
RU2375347C2 |
